[Treatment of life-threatening bleeding in obstetrics and gynaecology --NovoSeven (recombinant factor VIIa)].
The study offers the results from the application of recombinant factor VIIa (NovoSeven) in 19 patients with obstetric or gynaecological problems showing severe haemorrhage of non-surgical origin, which could not be controlled by standard therapy (surgery and resuscitation). Haematological and haemostaseological values as well as final outcome are being monitored. The role of the drug and its special indications in complex urgent treatment of life-threatening bleeding are being discussed. Conclusions. The use of NovoSeven (recombinant factor Vlla) on time and when indicated guarantees rapid and effective haemostasis. Thus laparotomy or relaparotomy can be avoided. If no effect is observed after the application of NovoSeven indicates bleeding from a major blood vessel, demanding laparotomy and surgery. The use of the drug leads to reducing the incidence of blood derivatives transfusions and (being a recombinant product)--no risk of transmissive infections.
Nikolov
A
A
Dimitrov
A
A
Tanchev
S
S
Platikanov
V
V
Nacheva
A
A
Gateva
Zh
Zh
Gerganova
A
A
D015942:Factor VIIa / Q000737:chemistry / Q000235:genetics / Q000627:therapeutic use*; D005260:Female; D006176:Gynecology; D006470:Hemorrhage / Q000188:drug therapy*; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D008954:Models, Biological; D015394:Molecular Structure; D009774:Obstetrics; D011247:Pregnancy; D011994:Recombinant Proteins / Q000737:chemistry / Q000627:therapeutic use; D016896:Treatment Outcome
D006490:Hemostatics; D011994:Recombinant Proteins; D015942:Factor VIIa